LAKE ZURICH, Ill., June 20, 2019 – Fresenius Kabi announced today the immediate availability in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a medication for sedation of non-intubated patients prior to and/or during surgical and other procedures.
Fresenius Kabi Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 20 mL vials, as well as 50 mL and 100 mL bottles. The introduction of these Dexmedetomidine presentations
JUNE 20, 2019